Advanced Search

 

Study ID Status Title Patient Level Data
NUCB3001 Completed A Randomized, Controlled 3TCTM Double-Blinded Trial to Compare the Safety and Efficacy of 3TCTM in Combination with Zidovudine (ZDV) Versus Zidovudine Monotherapy in Treating HIV-1 Infected Patients Who Are Zidovudine Therapy-Naïve With a CD4 Cell Count Between 100 - 400 cells/mm3.
NUCB3002 Completed A Randomized, Controlled, Lamivudine (3TCTM) Double-Blinded Trial to Compare the Safety and Efficacy of Zidovudine (ZDV) Monotherapy Versus Lamivudine Plus ZDV in Combination in Treating HIV-1 Infected Patients who are Zidovudine Therapy-Experienced With a CD4+ Cell Count Between 100cells/mm3 to ...
NUCB3007 Completed A Randomized, Controlled, Double-Blinded, Clinical End-Point Trial to Compare the Efficacy and Safety of 3TC Versus 3TC + Loviride Versus Placebo in the Treatment of HIV-1 Infected Persons Taking Concurrent Zidovudine-Containing Treatment Regimens With CD4 Counts Between 25cells/mm3 to 250cells/mm3
NUCB3009 Completed A Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Two Dosage Regimens of Lamivudine in Patients with Chronic Hepatitis B Infection
NUCB3010 Completed A Study of Lamivudine and Alpha-Interferon in Patients with Chronic Hepatitis B Infection Who are Interferon Treatment Naive
NUCB3014 Completed A Study of Lamivudine in Patients With HBeAb Positive Chronic Hepatitis B Infection; Week 52 (End of Treatment) Analysis
NUCB3017 Completed A Study of Extended Lamivudine Treatment for Hepatitis B Subjects Previously Enrolled in Phase II or Phase III Lamivudine Trials.
NUCB3018 Completed A Follow-On Study to Determine the Safety and Efficacy of Long-Term Lamivudine Treatment in Patients with Chronic Hepatitis B Infection (5 Year Treatment Plus 6 Months Off-treatment Follow-Up) Study Listed on ClinicalStudyDataRequest.com
NUCB3026 Completed A Double-Blind, Placebo-Controlled Study Of Lamivudine In Subjects In China With Chronic Hepatitis B Infection Followed By Long-Term (5 Years) Lamivudine Treatment Study Listed on ClinicalStudyDataRequest.com
NUCB3027 Completed Phase III trial to compare the efficacy of the combination zidovudine/lamivudine taken either as a single tablet of a fixed-dose combination (zidovudine 300 mg/lamivudine 150 mg) twice daily, or as zidovudine (two 100 mg capsules, three times daily) and lamivudine (one 150 mg tablet, twice daily ...
NUCB4006 Completed A Double-blind Placebo Controlled Clinical End-points Trial of Lamivudine in Patients with Hepatitis B Related Cirrhosis Study Listed on ClinicalStudyDataRequest.com
NZTA1001 Completed An Evaluation of the Bioequivalence of a Combined Formulated Tablet Compared to Epivir and Retrovir Administered Concurrently and the Effect of Food on Absorption
NZTA4001 Completed A Randomized, Multicenter Study of EPIVIR 150mg BID, RETROVIR 200mg TID and a Protease Inhibitor Versus 3TC 150mg/ZDV 300mg Fixed-Dose Tablet Given BID with a Protease Inhibitor in HIV-1 Infected Subjects
NZTA4003 Completed A Pharmacokinetic Evaluation of Methadone Following Co-administration with Combivir in Opiate-dependent Subjects
NZTA4006 Completed A Phase IIIB, Open-Label, Randomized Study of the Effect of an Education Intervention on Virologic Outcomes, Adherence, Immunologic Outcome, and Health Outcomes in HIV-Infected Subjects from Under-Represented Populations Treated with Triple Nucleoside Therapy (COMBIVIR, Lamivudine 150mg/Zidovudi ...
NZTA4007 Completed A Phase IIIB, Open-Label, Pilot Study to Evaluate the Efficacy, Tolerability, and Health Care Resource Use in HIV-Infected Incarcerated Subjects Treated Twice Daily for 24 Weeks with COMBIVIR (Lamivudine 150mg/Zidovudine 300mg) plus ZIAGEN (Abacavir) 300mg.
NZTA4008 Completed A Phase IV, 48-week, Randomized, Open-label, Multicenter Trial of Abacavir (300mg BID)/Efavirenz (600mg QD)/Didanosine (400mg QD) +/- Hydroxyurea (500mg BID) in HIV-1 Infected Subjects Failing Initial Therapy with 3TC/ZDV (or d4T) +/- Protease Inhibitors
O7921353 Completed A Single-dose, Two-centre, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Two Kinds of AlbendazoleTablet Formulations in Healthy Chinese Adult Males
ODN1003 Completed A randomised, placebo-controlled, four-period, crossover study of 8 days repeat dosing of a new chemical entity (NCE), fluticasone propionate (200 µg od) and placebo (blinded for NCE vs placebo) to evaluate the efficacy and safety using the Vienna Challenge Chamber in subjects with allergic rhinitis. Study Listed on ClinicalStudyDataRequest.com
OFA110867 Completed Clinical phase I/IIA study of subcutaneously administration of Ofatumumab in Rheumatoid Arthritis patients on stable dose Methotrexate
OHB10001 Completed An open label positron emission tomography study to evaluate dopamine transporter occupancy, as measured by 11C-bCIT-FE following 150mg WELLBUTRIN SR twice daily for 8 days, in healthy male volunteers.
OLA103920 Completed A randomised, single and repeat dose, double-blind, placebo controlled study to assess the safety, tolerability and pharmacokinetics of GSK615915 in healthy volunteers and mild asthmatics.
OM8 Afib Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation Study Listed on ClinicalStudyDataRequest.com
OM9L Completed A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered with Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects Study Listed on ClinicalStudyDataRequest.com
OMB_HX_CD20_001 Completed An open-label, international, multicenter, dose escalating, Phase I/II study of HuMax-CD20 in patients with relapsed or refractory follicular lymphoma grade I-II

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.